E-Learning

Nvidia stock sank more than 2% early Tuesday, putting the AI chipmaker down 14% from its record high closing price of $148.88 in early November.

Professional investors have become “super bullish” on stocks, according to a popular Bank of America survey. That doesn’t bode well for the market’s short-term returns.

Retail sales increased in November amid a strong start to the holiday shopping season.

Here’s what could be next for SoundHound AI.

EVgo said its largest investor would be selling 23 million shares of Class A common stock, sending them sharply lower Tuesday morning.

Discovering breakout stocks requires analysis and intuition. Here are seven tips to spot future winners now.

Tesla upgraded, MongoDB initiated: Wall Street's top analyst calls

$90 million worth of PENGU has traded in its first hour of release.

The stocks of the ‘Magnificent Seven’ technology giants will likely continue to outperform in 2025, even though a market crash is now “inevitable,” Bank of America’s analysts have said.

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug